Contractor will perform testing of potential anti-viral compounds utilizing cell lines infected with HTLV III/LAV, human AIDS virus. Testing will be conducted in vitro at the rate of 5,000 tests per year. A BL-3 facility will be used for this testing. Contractor will maintain and manage cell lines and virus for testing of experimental agents, prepare these agents for testing, and report testing results as specified. Contractor may also conduct in vivo testing with a limited number of potential active compounds identified by the in vitro screening effort. Cell lines to be utilized for this testing will be specified and furnished by the Government, as will experimental agents for testing.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM087237-000
Application #
3615786
Study Section
Project Start
1988-08-15
Project End
1993-07-14
Budget Start
1988-08-15
Budget End
1989-07-14
Support Year
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205
Buckheit Jr, R W; Hollingshead, M G; Germany-Decker, J et al. (1993) Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res 21:247-65